# Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium

> **NCT03682497** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 68 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** AZD9977
- **DRUG:** Spironolactone

## Key facts

- **NCT ID:** NCT03682497
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-01
- **Primary completion:** 2020-03-31
- **Final completion:** 2020-03-31
- **Target enrollment:** 68 (ACTUAL)
- **Why stopped:** Attendance at study sites carries risk of COVID-19 infection. Non-attendance at planned study site visits has unacceptable study related patient safety risk.
- **Last updated:** 2020-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03682497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03682497, "Study in HFpEF Patients to Compare the Effect of AZD9977 and Spironolactone on Serum Potassium". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03682497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*